Table 3.
Selected Clinical Trials of CAR-T Cells and ICIs
| Sponsor | Phase | Target | Trial Title | CAR | ICI | NCT No.: ClinicalTrials.gov | Status |
|---|---|---|---|---|---|---|---|
| City of Hope Medical Center | I | glioma | IL13Ralpha2-targeted chimeric antigen receptor (CAR) T cells with or without nivolumab and ipilimumab in treating patients with recurrent or refractory glioblastoma | IL13Ralpha2 | nivolumab, ipilimumab | NCT04003649 | recruiting |
| University of Pennsylvania | I | glioblastoma | phase I study of EGFRvIII-directed CAR T cells combined with PD-1 inhibition in patients with newly diagnosed, MGMT-unmethylated glioblastoma | EGFRvIII | pembrolizumab | NCT03726515 | active |
| University of Pennsylvania | I/II | DLBCL; FL; MCL | pembrolizumab in patients failing to respond to or relapsing after CAR T cell therapy for relapsed or refractory lymphomas | CD19 | pembrolizumab | NCT02650999 | active |
| Fred Hutchinson Cancer Research Center | I | DLBCL; mediastinal (thymic) large B cell lymphoma | JCAR014 and durvalumab in treating patients with relapsed or refractory B cell non-Hodgkin lymphoma | CD19 | durvalumab | NCT02706405 | recruiting |
| Baylor College of Medicine | I | neuroblastoma | 3rd generation GD-2 chimeric antigen receptor and iCaspase suicide safety switch, neuroblastoma (GRAIN) | GD2 | pembrolizumab | NCT01822652 | active, not recruiting |
ICI, immune checkpoint inhibitor, DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma.